---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-455789"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2026-11-10T22:30:46+00:00"
generated_at: "2026-11-10T22:32:08.956728+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Spero Therapeutics appoints William Ho to board as Patrick Vink resigns

## Summary
- Patrick Vink, M.D., resigned from Spero's board effective Nov. 10, 2026, including roles as Nominating and Corporate Governance Committee chair and Compensation Committee member.
- The company said Vink's resignation was not due to any dispute or disagreement and thanked him for 11 years of service.
- William Ho, M.D., Ph.D., was appointed Class II director effective Nov. 10, 2026, and will serve on the Development Committee.
- Ho will receive a $40,000 annual board retainer, $5,000 committee retainer and an option for 100,000 shares vesting monthly over one year.
- Ho was RAPT Therapeutics' chief medical officer from 2015 to December 2025; the filing cites RAPT's $2.2 billion acquisition by GSK finalized in March 2026.

## SEC filing metadata
- accession: 0001193125-26-455789
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2026-11-10T22:30:46+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312526455789/0001193125-26-455789-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312526455789/d196561d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-455789
- JSON: https://secwatch.observer/filing/0001193125-26-455789.json
- Plain text: https://secwatch.observer/filing/0001193125-26-455789.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.